Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports

The document discusses two case reports of alopecia areata (AA) treated with upadacitinib, a JAK1 inhibitor. The study highlights the varied clinical presentations of AA, including a classical form of AA universalis and a case with coexisting sarcoidosis. Treatment with upadacitinib resulted in satisfactory outcomes, with visible regrowth of vellus hair within 3-6 months. The findings suggest that early treatment with JAK inhibitors like upadacitinib can improve the quality of life for AA patients both physically and psychologically, without worsening sarcoidosis-related skin lesions.